Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next generation Sonata® System 2.1 for Transcervical Fibroid Ablation (TFA).
The Sonata technology platform integrates the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. This next generation system incorporates additional features developed through close collaboration with experienced physicians and validated with rigorous testing, to improve usability and streamline workflow.
Having implemented the advanced system in January at Spital Oberengadin – Schweiz (Samedan, Switzerland), Dr. Ladina Christoffel has performed TFA using Sonata 2.1 in several fibroid cases since the restart of elective procedures at the facility at the end of April. “The significant improvement to the controls on the Sonata RFA handpiece enables our team to perform TFA with increased confidence and improved efficiency,” said Dr. Christoffel. “We implemented Sonata TFA in our fibroid treatment offering in view of the impressive published patient outcomes. Based upon our experience, it has now become a first-line fibroid treatment.”
The new advances in Sonata 2.1 include a new integrated treatment device design that enables all procedure steps to be performed on the sterile field and in the palm of the physician’s hand; a smaller more ergonomic radio-frequency ablation handpiece with improved controls; and importantly provides a superior graphical user interface with new enhanced SMART technology procedural cues. In addition, the new design significantly improves the manufacturability of the device.
“FDA clearance for our advanced Sonata System 2.1 is a noteworthy achievement. The feedback from European physicians on the improved system design and performance during the early 2020 launch in Europe is positive. This contributed to a significant increase in procedure volumes,” explained Christopher Owens, President and CEO of Gynesonics. “We look forward to introducing the technology to the U.S. market and others around the globe. This highlights Gynesonics’ commitment to consistently deliver breakthrough advances for women’s health, while continuing to demonstrate our clinical significance through published peer-reviewed evidence.”
See Full Press Release: Gynesonics Receives FDA Clearance to Market Next Generation Sonata® System 2.1 | Business Wire
Written by: Gynesonics
Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.